DRG Epidemiology’s coverage of hepatitis C virus (HCV) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of HCV for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology’s HCV forecast will answer the following questions:
Of all people with HCV, how many in each country have been formally diagnosed?
Of all people diagnosed with HCV, how many in each country are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HCV over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
DRG Epidemiology provides at least ten years of forecast data for the following HCV patient populations:
Total prevalent cases by viremic status.
Diagnosed prevalent cases by drug-treated subpopulation.
Total incident and total prevalent cases by subpopulation.
Total Prevalence of Hepatitis C Virus per 1,000 People of All Ages per Year in 2021 and 2031
Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of HCV over the Next Ten Years
Analysis of the Viremic Prevalent Cases of Hepatitis C Virus in 2021 by Genotype
Analysis of the Prevalent Cases of Hepatitis C Virus in 2017 by Diagnosed and Drug-Treated Status
Total Seroprevalent Cases
Total Incident Cases
Total Prevalent Viremic Cases
HCV Genotype Prevalence
Cirrhotic Status by Genotype
Diagnosed Prevalent Cases
Drug-Treated Prevalent Cases
Studies Included in the Analysis of Hepatitis C Virus
Studies Excluded from the Analysis of Hepatitis C Virus
Risk/Protective Factors for Hepatitis C Virus
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.